| Name | calcium channel (protein family or complex) |
|---|---|
| Synonyms | calcium channel |
| Name | piperazine |
|---|---|
| CAS | piperazine |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 12211084 | Thumen A, Qadri F, Sarkar R, Moser A: GBR-12909 effect on outflow depends on phosphorylation in the caudate nucleus of the rat. Synapse. 2002 Nov;46(2):72-8. These results suggest a complex and strong influence of phosphorylation on GBR-12909 effects on calcium channel-dependent DA outflow at low-affinity piperazine binding sites in slices of the rat caudate nucleus in vitro. |
82(1,1,1,2) | Details |
| 18987207 | Newton PM, Zeng L, Wang V, Connolly J, Wallace MJ, Kim C, Shin HS, Belardetti F, Snutch TP, Messing RO: A blocker of N- and T-type voltage-gated channels attenuates -induced intoxication, place preference, self-administration, and reinstatement. J Neurosci. 2008 Nov 5;28(45):11712-9. We demonstrate that pretreatment with the novel mixed N-type and T-type calcium channel antagonist 1-(6,6-bis (4-fluorophenyl) hexyl)-4-(3,4,5-trimethoxybenzyl) piperazine (NP078585) reduced intoxication. |
32(0,1,1,2) | Details |
| 11205066 | Matthew CB, Sils IV: Flunarizine pretreatment attenuates hyperthermia-induced extravasation in rats. Pflugers Arch. 2000 Nov;441(1):88-93. This work assessed the potential of the calcium channel blocker (E)-1-bis (4-fluorophenyl) methyl-4-(3-phenyl-2-propenyl) piperazine dihydrochloride (flunarizine) as a pretreatment to ameliorate this extravasation. |
6(0,0,1,1) | Details |
| 19372737 | Newton PM, Messing RO: The N-type calcium channel is a novel target for treating use disorders. Channels. 2009 Mar-Apr;3(2):77-81. Epub 2009 Mar 28. |
4(0,0,0,4) | Details |
| 17150365 | Park JH, Choi JK, Lee E, Lee JK, Rhim H, Seo SH, Kim Y, Doddareddy MR, Pae AN, Kang J, Roh EJ: Lead discovery and optimization of T-type calcium channel blockers. Bioorg Med Chem. 2007 Feb 1;15(3):1409-19. Epub 2006 Nov 10. Among the library with 5 features, alkaneamide derivatives (7b, 9j, 11b, 11g, 11h) with 4-arylsubstituted piperazine showed better IC (50) values than Mibefradil. |
3(0,0,0,3) | Details |
| 15927838 | Mehanna AS, Kim JY: Design, synthesis, and biological testing of thiosalicylamides as a novel class of calcium channel blockers. Bioorg Med Chem. 2005 Jul 1;13(13):4323-31. Compounds of the current series showed optimum activity when the aliphatic alkyl chain on the salicylamide is part of a piperidine or piperazine ring system substituted at the terminal with a benzyl group. |
3(0,0,0,3) | Details |
| 16868792 | Cui XY, Zhao X, Chu QP, Chen BQ, Zhang YH: Influence of on the behavior of -treated mice in the elevated-plus maze test. J Neural Transm. 2007 Feb;114(2):155-60. Epub 2006 Aug 1. The present study was undertaken to investigate the effect of a L-type calcium channel blocker (CCB), on the behavior of -treated mice in the elevated plus-maze (EPM). also attenuated the anxiogenic effect of 1-(3-Chlorophenyl) piperazine (mCPP, 0.7 mg/kg, i.p.) and (5-HTP, 30 mg/kg, i.p.). |
2(0,0,0,2) | Details |
| 18095903 | Melloni C, Newby LK: Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. Expert Rev Cardiovasc Ther. 2008 Jan;6(1):9-16. Ranolazine is a piperazine derivative believed to reduce anginal symptoms by preventing ischemia-mediated and overload in myocardial cells through inhibition of the late current (late INa). Three small studies demonstrated the antianginal efficacy of ranolazine alone and in combination with betablockers or calcium channel blockers on conventional end points such as total exercise duration and time to ischemia/angina on a treadmill; however, questions of safety related to QT prolongation, efficacy in women and potential utility in higher risk populations remained. |
1(0,0,0,1) | Details |
| 16636115 | Turner D, Lurie Y, Finkelstein Y, Schmid T, Gopher A, Kleid D, Bentur Y: Pediatric cinnarizine overdose and toxicokinetics. Pediatrics. 2006 May;117(5):e1067-9. Epub 2006 Apr 24. Cinnarizine, a piperazine derivative, is a widely prescribed medication for the treatment of vestibular disorders and motion sickness. Cinnarizine has antihistaminic, antiserotoninergic, antidopaminergic, and calcium channel-blocking properties. |
1(0,0,0,1) | Details |
| 17610910 | Kraus RL, Li Y, Jovanovska A, Renger JJ: Trazodone inhibits T-type channels. Neuropharmacology. 2007 Aug;53(2):308-17. Epub 2007 May 26. Our data suggest that T-type calcium channel antagonism may contribute to the pharmacology of trazodone and its reported neurological effects. |
1(0,0,0,1) | Details |
| 11259531 | McKune CM, Watts SW: Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. J Pharmacol Exp Ther. 2001 Apr;297(1):88-95. Our hypothesis was further supported by the finding that antagonists with affinity for the 5-HT2A receptor, ketanserin, 1-(1-naphthyl) piperazine, spiperone, and LY53857, reduced -induced contraction. The L-type calcium channel blockers nifedipine and nitrendipine, PLC inhibitor 2-nitro-4-carboxyphenyl N,N-diphenylcarbamate, and kinase inhibitors and PD 098,059 all shifted and/or reduced maximum contraction to |
1(0,0,0,1) | Details |
| 19371580 | Belardetti F, Ahn S, So K, Snutch TP, Phillips AG: Block of voltage-gated channels stimulates efflux in rat mesocorticolimbic system. Neuropharmacology. 2009 May-Jun;56(6-7):984-93. Epub 2009 Feb 11. Here we investigate changes in mesocorticolimbic DA efflux following administration of NP078585, a novel orally available calcium channel blocker exhibiting high affinity block of N- and T-types versus P/Q- and L-types. |
1(0,0,0,1) | Details |